1. Home
  2. RILYP vs CGEN Comparison

RILYP vs CGEN Comparison

Compare RILYP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RILYP
  • CGEN
  • Stock Information
  • Founded
  • RILYP 1973
  • CGEN 1993
  • Country
  • RILYP United States
  • CGEN Israel
  • Employees
  • RILYP N/A
  • CGEN N/A
  • Industry
  • RILYP Investment Managers
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RILYP Finance
  • CGEN Health Care
  • Exchange
  • RILYP Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • RILYP N/A
  • CGEN 167.4M
  • IPO Year
  • RILYP N/A
  • CGEN 2000
  • Fundamental
  • Price
  • RILYP $2.19
  • CGEN $1.65
  • Analyst Decision
  • RILYP
  • CGEN
  • Analyst Count
  • RILYP 0
  • CGEN 0
  • Target Price
  • RILYP N/A
  • CGEN N/A
  • AVG Volume (30 Days)
  • RILYP 17.9K
  • CGEN 265.0K
  • Earning Date
  • RILYP 01-01-0001
  • CGEN 08-05-2025
  • Dividend Yield
  • RILYP 39.24%
  • CGEN N/A
  • EPS Growth
  • RILYP N/A
  • CGEN N/A
  • EPS
  • RILYP N/A
  • CGEN N/A
  • Revenue
  • RILYP $854,383,000.00
  • CGEN $27,589,000.00
  • Revenue This Year
  • RILYP N/A
  • CGEN N/A
  • Revenue Next Year
  • RILYP N/A
  • CGEN $173.80
  • P/E Ratio
  • RILYP N/A
  • CGEN N/A
  • Revenue Growth
  • RILYP N/A
  • CGEN N/A
  • 52 Week Low
  • RILYP $1.73
  • CGEN $1.13
  • 52 Week High
  • RILYP $20.00
  • CGEN $2.66
  • Technical
  • Relative Strength Index (RSI)
  • RILYP 53.39
  • CGEN 51.95
  • Support Level
  • RILYP $1.73
  • CGEN $1.58
  • Resistance Level
  • RILYP $2.00
  • CGEN $1.81
  • Average True Range (ATR)
  • RILYP 0.22
  • CGEN 0.08
  • MACD
  • RILYP 0.03
  • CGEN -0.01
  • Stochastic Oscillator
  • RILYP 78.95
  • CGEN 20.00

About RILYP B. Riley Financial Inc.

B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: